A.L. Jackman - Concepedia

Author

A.L. Jackman

Also Known As

A Jackman, A L Jackman, A. Jackman, A. L Jackman, A. L. JACKMAN, A. L. Jackman, A.L. Jackman, AL Jackman, Ainsley Jackman, Alex B. Jackman

Publications

959

Citations

H-Index

Concepts

All Affiliations

Institute of Cancer Research

About

A.L. Jackman is an author at Institute of Cancer Research specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	769
2	Natural Sciences	5	5	587
3	Biochemistry	5	5	587
4	Health Sciences	2	2	125
5	Biomolecular Engineering	1	1	12

A.L. Jackman

Publications

924

Citations

H-Index

Page 1

	Year	Citations
ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. A.L. Jackman, G A Taylor, William Gibson, PubMed Pharmaceutical SciencePharmacotherapyPharmaceutical ChemistryTumor BiologyMedicinal Chemistry	1991	359
Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines A.L. Jackman, Rosemary Kimbell, Melody Brown, British Journal of Cancer Natural SciencesMolecular BiologyResistance Mutation (Virology)Human Cell LinesGene Expression	1995	102
A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargyl-5,8-dideazafolic acid, CB3717. A H Calvert, D Alison, S. J. Harland, Journal of Clinical Oncology PathologyPharmacotherapyPharmaceutical ChemistryPre-clinical PharmacologyDrug Resistance	1986	102
Comparison of thymidylate synthase (TS) protein up-regulation after exposure to TS inhibitors in normal and tumor cell lines and tissues. S J Welsh, Jenny Titley, Lisa Brunton, PubMed ImmunologyThymidylate SynthaseImmunotherapyTumor BiologyOncology	2000	75
Activity of the thymidylate synthase inhibitor 2-desamino-N10-propargyl-5,8-dideazafolic acid and related compounds in murine (L1210) and human (W1L2) systems in vitro and in L1210 in vivo. A.L. Jackman, G A Taylor, BM O'Connor, PubMed Molecular PharmacologyMedicinal ChemistryBiosynthesisTs-inhibitory ActivityPharmaceutical Chemistry	1990	61
Molecular characterisation of two cell lines selected for resistance to the folate-based thymidylate synthase inhibitor, ZD1694 SJ Freemantle, A.L. Jackman, LR Kelland, British Journal of Cancer Molecular CharacterisationBiochemistryNatural SciencesBiochemical GeneticsMolecular Biology	1995	36
Relationships between resistance to cisplatin and antifolates in sensitive and resistant tumour cell lines Lloyd R. Kèlland, Rosemary Kimbell, Anthea Hardcastle, European Journal of Cancer OncologyMedicineCancer BiologyAnti-cancer AgentCancer Treatment	1995	30
Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717). A H Calvert, Newell, A.L. Jackman, PubMed Cb 3717Molecular PharmacologyMedicinal ChemistryChemoprevention StrategyBiochemistry	1987	29
Analysis of thymidylate synthase gene amplification and of mRNA levels in the cell cycle. A. Imam, Philip H. Crossley, A.L. Jackman, Journal of Biological Chemistry Amplified Ts GenesMrna LevelsProtein ExpressionCell DivisionGenetics	1987	29
Comparison of plasma and tissue levels of ZD1694 (Tomudex), a highly polyglutamatable quinazoline thymidylate synthase inhibitor, in preclinical models G. Wynne Aherne, Emma L. Ward, Nina Lawrence, British Journal of Cancer Preclinical ModelsMedicineMolecular BiologyTissue LevelsPharmacology	1998	28

Page 1